Xie Xiaoyu – Trademark Portfolio
Entity Type: 01
Xie Xiaoyu holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 6 filings in this category. The portfolio also extends into Class 28 (Toys & Sporting Goods) across 3 Nice Classification classes. Currently, 7 trademarks are registered and 1 is pending. Notable registered marks include SUNNOTE, CURVECITY, ICEFOLWER, STRONCHUAN, and WILD FAIRY. The owner is based in Huizhou, Guangdong.
Rm. 205, Bldg. 5, No. 1, Yajule Ave.
Ruhu Twon, Huicheng Dist.
Huizhou, Guangdong , CN
Showing of trademarks Trademarks
Trademark Classifications
Xie Xiaoyu's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Games and playthings; gymnastic and sporting articles; decorations for Christmas trees
Coffee, tea, cocoa and artificial coffee; rice; tapioca and sago; flour and preparations
Frequently Asked Questions
How many trademarks does Xie Xiaoyu have?
Xie Xiaoyu has 10 U.S. trademarks filed with the USPTO. Of these, 7 registered, 1 pending, 1 cancelled.
What trademark classes does Xie Xiaoyu file in?
Xie Xiaoyu files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 28 (Toys & Sporting Goods), Class 30 (Staple Foods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Xie Xiaoyu's most well-known trademarks?
Xie Xiaoyu's registered trademark portfolio includes well-known marks such as SUNNOTE, CURVECITY, ICEFOLWER, STRONCHUAN, and WILD FAIRY. These are among 7 currently registered trademarks in the portfolio.
What is Xie Xiaoyu's trademark registration success rate?
Xie Xiaoyu has a 88% trademark registration rate, with 7 out of 8 resolved applications resulting in successful registration. Currently, 1 application is pending review.